Linc-OIP5 working as a ceRNA of miR-616 promotes PON1 expression in HUEVC cells.
Coronary atherosclerosis
Linc-OIP5
PON1
miR-616
nitric oxide
superoxide dismutase
Journal
International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
01
2020
accepted:
04
03
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
2
5
2020
Statut:
epublish
Résumé
Coronary atherosclerosis affects human health all over the world. PON1 was found to be associated with coronary atherosclerosis but the specific mechanism is still unclear. Non-coding RNA plays an important role in many diseases. In recent years, studies have focused on non-coding RNA in coronary atherosclerosis. In this study, we investigated the effect of non-coding RNA Linc-OIP5 on PON1 expression. Results showed that in the serum of patients with coronary atherosclerosis, there was lower PON1 activity and PON1 level, the same trend in Linc-OIP5, and the opposite trend in miR-616 expression. Through further cell experiments, with up-regulation or down-regulation of Linc-OIP5 and miR-616, we found that Linc-OIP5 positively regulated the expression of PON1 gene and its protein level, while miR-616 negatively regulated the expression of PON1 gene and protein. Through further functional experiments, we also found that the levels of superoxide dismutase (SOD) and nitric oxide (NO) related to oxidative stress also had corresponding changes. Further dual luciferase reporter assay demonstrated that Linc-OIP5 regulated PON1 expression as a ceRNA of miR-616. Thus Linc-OIP5 working as a ceRNA of miR-616 apparently promotes PON1 expression in HUEVC cells and Linc-OIP5 and miR-616 may be an ideal target for the treatment of coronary atherosclerosis in the future.
Types de publication
Journal Article
Langues
eng
Pagination
730-737Informations de copyright
IJCEP Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Cancer Discov. 2011 Oct;1(5):391-407
pubmed: 22096659
J Cell Sci. 2011 Dec 1;124(Pt 23):4115-24
pubmed: 22135361
Oxid Med Cell Longev. 2018 Jul 31;2018:2673076
pubmed: 30151068
Oncotarget. 2016 Dec 27;7(52):85876-85887
pubmed: 27811377
Int J Mol Sci. 2014 Nov 14;15(11):20997-1010
pubmed: 25405733
Drug Metab Dispos. 2000 Nov;28(11):1335-42
pubmed: 11038162
Science. 2001 Oct 26;294(5543):858-62
pubmed: 11679671
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Biochimie. 2017 Jan;132:19-27
pubmed: 27771368
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
Cell. 2011 Oct 14;147(2):358-69
pubmed: 22000014
Circ Res. 2017 Feb 17;120(4):713-735
pubmed: 28209797
Am J Transl Res. 2019 Mar 15;11(3):1827-1834
pubmed: 30972206
J Cell Biochem. 2020 Jan 3;:
pubmed: 31898365
Clin Lab. 2018 Jun 1;64(6):1049-1053
pubmed: 29945323
Eur Heart J Suppl. 2016 May;18(Suppl F):F2-F11
pubmed: 28533724
Cell J. 2020 Oct;22(3):375-385
pubmed: 31863664
J Cell Mol Med. 2018 Oct;22(10):5062-5075
pubmed: 30079603
Nature. 2011 May 19;473(7347):317-25
pubmed: 21593864
J Mol Cell Cardiol. 2012 Mar;52(3):587-95
pubmed: 22226905
Kaohsiung J Med Sci. 2012 Dec;28(12):631-40
pubmed: 23217354
Nutr Metab Cardiovasc Dis. 2018 Nov;28(11):1175-1187
pubmed: 30314869
Rev Med Chir Soc Med Nat Iasi. 2003 Jul-Sep;107(3):502-11
pubmed: 14756052